Abeona Therapeutics Inc. (ABEO) News
Filter ABEO News Items
ABEO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABEO News Highlights
- ABEO's 30 day story count now stands at 2.
- Over the past 8 days, the trend for ABEO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC are the most mentioned tickers in articles about ABEO.
Latest ABEO News From Around the Web
Below are the latest news stories about ABEONA THERAPEUTICS INC that investors may wish to consider to help them evaluate ABEO as an investment opportunity.
Those who invested in Abeona Therapeutics (NASDAQ:ABEO) a year ago are up 98%These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do... |
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On December 14, 2023, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to four individuals hired by Abeona, which equity awards relate to, in the |
ABEO: BLA for Pz-Cel (EB-101) Accepted with Priority Review; PDUFA Date of May 25, 2024…By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update BLA Accepted with Priority Review; PDUFA Action Date of May 25, 2024 On November 27, 2023, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) has accepted with Priority Review the Biologics License Application (BLA) to seek approval for prademagene zamikeracel |
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel), Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of pat |
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call TranscriptAbeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call Transcript November 16, 2023 Operator: Greetings, and welcome to the Abeona Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions]. Please note this conference is being recorded. I will now turn the conference over to your host, Mr. Greg Gin. Sir, you may begin. Greg Gin: Thank you, […] |
ABEO: BLA Submitted for Pz-Cel (EB-101); Increasing Valuation to $11.00…By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update BLA Submitted; Awaiting FDA Decision on Acceptance and Priority Review On September 26, 2023, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the company had submitted the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to seek approval for prademagene zamikeracel (pz-cel; |
Q3 2023 Abeona Therapeutics Inc Earnings CallQ3 2023 Abeona Therapeutics Inc Earnings Call |
Abeona Therapeutics Inc (ABEO) Reports Q3 2023 Financial Results and Advances in Commercial ...Key Developments Include BLA Submission for RDEB Treatment and Strengthened Financial Position |
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate DevelopmentsAbeona’s first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority review and acceptance of BLA for pz-cel (prademagene zamikeracel, formerly known as EB-101) in recessive dystrophic epidermolysis bullosa (RDEB) expected by late-November 2023 Initiated commercial readiness activities for potential U.S. launch of pz-cel CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for |
The 7 Most Undervalued Penny Stocks to Buy in October 2023Undervalued penny stocks offer tremendous return for investors with an appetite for risk but these shares are relatively safe as well. |